ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018
DALLAS, October 17, 2011 /PRNewswire/ –
This research report ‘Depression Therapeutics – Pipeline Assessment and
Market Forecasts to 2018′ valued the global depression therapeutics market
at $4.6 billion in 2010, and expects it to grow at a compound annual growth
rate (CAGR) of 3.2% over the next seven years to reach $10.9 billion by
2018. The depression therapeutics market
will witness the patent
expiry of Lexapro in 2012, Cymbalta in 2013 and Effexor XR in 2014. However,
the launch of new drugs such as Viibryd, LuAA21004, Levomilnacipran (F2695)
and AGO178 (in the US), offering better efficacy and safety profiles, along
with disease modifying properties, will help to sustain steady and positive
growth during the forecast period to 2018.
The report is an essential source of information and analysis on the
global depression therapeutics market. The report identifies the key trends
shaping and driving the global depression market. The report also provides
insights in to the prevalent competitive landscape and the emerging players
expected to significantly alter the market positioning of the current market
leaders. Most importantly, the report provides valuable insights in to the
pipeline products within the global depression market. This report is built
using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by a team of industry experts.
The report provides information on the key drivers and challenges of the
depression market. Its scope includes:
- Annualized global depression market revenues data from 2005 to 2010, forecast for eight years to 2018. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Glutamate receptor which includes Metabotropic glutamate receptors 2 antagonist, Glutamate receptor 2 and 3 antagonist, Group II metabotropic glutamate receptors antagonist, Metabotropic glutamate receptor 5 antagonist, N-methyl d-aspartate receptor (NMDAR) antagonist, Alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) potentiator whereas Seretonin receptor modulators which includes 5-HT3, 5-HT7 and 5-HT1A receptor receptor agonist and 5-HT transporter inhibitor, 5-HT3 and 5-HT2C antagonist, 5HT reuptake blockade, 5HT2 agonism, 5HT1A agonism, and 5HT1D central receptors agonist, 5-HT2A/5-HT2C/D2/D3 receptor antagonist followed by Triple-reuptake inhibitors, Monoamine oxidase (MAO) modulators, Arginine vasopressin antagonists and so on. - Analysis of the current and future competition in the global depression market. Key market players covered are Otsuka Holdings Co., Ltd, Forest Laboratories, H Lundbeck A/s, Eli Lilly, Targacept Inc., Fabre-Kramer Pharmaceuticals, Inc., Euthymics Bioscience, Inc., AstraZeneca PLC, and Novartis/Servier. - An insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the depression therapeutics market. - Analysis of key recent licensing and partnership agreements in the depression therapeutics market.
Reasons to buy
The report will enhance your decision making capabilities. It will allow
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines. - Develop business strategies by understanding the trends shaping and driving the global depression market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global depression market in the future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potential strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What's the next big thing in the global depression market landscape? - Identify, understand and capitalize.
Explore Table of Contents and get your copy of the report @
Other New Market Research Offerings:
- Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 [http://www.reportsnreports.com/reports/134747-systemic-lupus-erythematosus-therapeutics-sle-pipeline-assessment-and-market-forecasts-to-2018.html ] - - U.S. Hepatitis C Market [http://www.reportsnreports.com/reports/134898-us-hepatitis-c-market.html ] - Vital Signs - Consolidating Digital Pathology into Enterprise Imaging IT: How Much Longer to Go? [http://www.reportsnreports.com/reports/132861-vital-signs-consolidating-digital-pathology-into-enterprise-ima.html ] - Strategic Analysis of the Indian Health Ingredients Market [http://www.reportsnreports.com/reports/132851-strategic-analysis-of-the-indian-health-ingredients-market.html ]
ReportsnReports.com is an online market research
[http://www.reportsnreports.com ] library of 130,000+ reports and in-depth
studies of over 5000 micro markets. Our database includes reports by leading
publishers from across the globe. We provide 24/7 online and offline support
service to our customers.
Contact: Priyank Tiwari 7557 Rambler road, Suite 727, Dallas, TX 75231 Tel: +1-888-391-5441 firstname.lastname@example.org Visit our Market Research Blog [http://www.reportsnreportsblog.com ]